Coagulation Factor II Inhibitor Assay, Plasma
Prothrombin (factor II), encoded by the F2 gene, is a vitamin K–dependent serine protease synthesized by the liver and plays a central role in coagulation through its conversion to thrombin. Thrombin generation is essential for fibrin formation, platelet activation, and amplification of the coagulation cascade. In rare cases, individuals develop acquired inhibitors to prothrombin, most commonly immunoglobulin G antibodies, which neutralize factor II activity and result in impaired thrombin generation.
Factor II inhibitors are uncommon but clinically significant and may be associated with autoimmune disease, infections, malignancy, exposure to certain medications, or repeated transfusions of plasma-derived products. In some patients, inhibitors occur in association with lupus anticoagulant–hypoprothrombinemia syndrome, in which bleeding may occur despite the presence of lupus anticoagulant. Clinical presentation ranges from mild mucocutaneous bleeding to severe spontaneous hemorrhage.
Laboratory findings typically include a prolonged prothrombin time (PT) with markedly reduced factor II activity that does not correct on mixing studies, suggesting the presence of an inhibitor rather than a simple deficiency. The Factor II Inhibitor Assay is used to detect and confirm inhibitor-mediated reduction of prothrombin activity and to distinguish acquired inhibitors from congenital or acquired factor II deficiency due to decreased synthesis or consumption.
- Used in the evaluation of unexplained bleeding with reduced factor II activity
- To distinguish factor II deficiency from inhibitor-mediated loss of activity
- Useful in the assessment of autoimmune or antibody-mediated coagulation disorders, including lupus anticoagulant–hypoprothrombinemia syndrome
- Aids in the investigation of prolonged PT that fails to correct with mixing studies
Adults: 75-145%
Newborn infants or healthy premature infants may have decreased levels as low as > or =25%.
Usually this might persist for 2-3 months and before becomes normal.
Platelet-poor plasma, 5 mL (patients should ideally not be receiving warfarin, heparin, or direct oral anticoagulants at the time of collection if clinically feasible), sodium citrate (light-blue top vial).
Stability
- Ambient: 4 hrs.
- Refrigerated: 24 hrs.
- Frozen: 14 days.
- Semin Thromb Hemost. 2009 Jun;35(4):416-25. [PMID: 19598070]
- Semin Arthritis Rheum. 2009 Aug;39(1):61-5. [PMID: 18519152]
- Nat Rev Cardiol. 2025 Nov;22(11):896-912. [PMID: 40164778]
- Cardiol Ther. 2024 Mar;13(1):1-16. [PMID: 38306010]
- Br J Haematol. 2025 Nov 16. [PMID: 41243450]